Well Fargo on Vertex (VRTX) Hidden Pipeline - VX-787 for Influenza
Tweet Send to a FriendGet Alerts VRTX Hot Sheet
Price: $77.52 -1.16%
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 16 | New: 29
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 16 | New: 29
Trade VRTX Now!
Investors looking for a winner in the pharmaceutical space by find it in Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), think analysts at Wells Fargo.
The company has a flu candidate drug called VX-787, with results expected by year-end. If successful, it may have potential advantages vs. Tamiflu, and analysts at Wells say based on their analysis there is a "possibility the agent could show clinical activity", which would provide upside for the stock considering the fact that the street has assigned very little value to the drug.
"With VRTX shares down--in part due to concerns over Kalydeco's peak sales in G551D and concerns over less certainty on upcoming CF and HCV datapoints--we believe this would provide a much-needed positive clinical catalyst, with little downside risk given the low expectations," wrote analyst Brian Abrahams.
"Preclinical data reported by VRTX showed protection of rodents from flu-related death at a higher rate and with a longer dosing window than Tamiflu, with data in IP filings indicating an ability to reduce weight loss. Other data also show that its differentiated mechanism enables activity vs. Tamiflu-resistant strains, while retaining efficacy vs. potential pandemic reassortments," continued Abrahams.
Wells Fargo has an Outperform rating on Vertex with a price target of $60 to $62.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $40.50 yesterday, with a 52 week range of $26.75-$66.10.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The company has a flu candidate drug called VX-787, with results expected by year-end. If successful, it may have potential advantages vs. Tamiflu, and analysts at Wells say based on their analysis there is a "possibility the agent could show clinical activity", which would provide upside for the stock considering the fact that the street has assigned very little value to the drug.
"With VRTX shares down--in part due to concerns over Kalydeco's peak sales in G551D and concerns over less certainty on upcoming CF and HCV datapoints--we believe this would provide a much-needed positive clinical catalyst, with little downside risk given the low expectations," wrote analyst Brian Abrahams.
"Preclinical data reported by VRTX showed protection of rodents from flu-related death at a higher rate and with a longer dosing window than Tamiflu, with data in IP filings indicating an ability to reduce weight loss. Other data also show that its differentiated mechanism enables activity vs. Tamiflu-resistant strains, while retaining efficacy vs. potential pandemic reassortments," continued Abrahams.
Wells Fargo has an Outperform rating on Vertex with a price target of $60 to $62.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $40.50 yesterday, with a 52 week range of $26.75-$66.10.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Needham & Company Maintains Underpform on HP (HPQ), Says Positives Priced In
- Compuware (CPWR) Estimates Trimmed, PT Raised at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
